Evotec

Evotec axes 30% of assets as cost-cutting push hits pipeline

The company axed around 30% of its asset portfolio and offloaded clinical program EVT 201 as part of a broader, ongoing attempt to correct its course.

Nick Paul Taylor Apr 17, 2025 9:45am

Evotec, Novo collab debuts first 3 projects, adds 5 partners

Dec 12, 2024 2:27pm

Stanford economist is Trump's NIH pick—Chutes & Ladders

Dec 6, 2024 8:30am

Halozyme pulls Evotec bid after biotech was 'unwilling' to talk

Nov 22, 2024 10:46am

Diverse group of hands holding up US dollar banknotes of various denominations on green background - stock photo

Halozyme offers $2B for Evotec to expand beyond tech used by J&J

Nov 15, 2024 6:01am

Evotec attracts private equity buyout interest: report

Nov 11, 2024 9:17am